INmune Bio (NASDAQ:INMB) Price Target Raised to $23.00 at Scotiabank

INmune Bio (NASDAQ:INMB) had its price target boosted by Scotiabank from $22.00 to $23.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has a sector outperform rating on the stock.

INMB has been the subject of several other reports. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw started coverage on INmune Bio in a research report on Tuesday, January 28th. They set a “buy” rating and a $23.00 price target for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 price target for the company. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $21.00.

INmune Bio Price Performance

INMB stock opened at $8.25 on Tuesday. The stock has a market capitalization of $182.90 million, a P/E ratio of -3.78 and a beta of 1.87. The business has a 50-day moving average of $6.29 and a 200-day moving average of $6.09. INmune Bio has a fifty-two week low of $4.32 and a fifty-two week high of $14.74.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Financial Advocates Investment Management raised its stake in INmune Bio by 14.8% in the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock valued at $72,000 after buying an additional 2,000 shares during the period. Rhumbline Advisers raised its stake in INmune Bio by 16.9% in the fourth quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock valued at $78,000 after buying an additional 2,424 shares during the period. Fermata Advisors LLC raised its stake in INmune Bio by 10.0% in the fourth quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock valued at $219,000 after buying an additional 4,267 shares during the period. LPL Financial LLC raised its stake in INmune Bio by 33.0% in the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company’s stock valued at $89,000 after buying an additional 4,730 shares during the period. Finally, Jane Street Group LLC bought a new stake in INmune Bio in the third quarter valued at approximately $79,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.